Effects of mu-opioid receptor, ATP-banding cassette, subfamily B, member 1 gene, CYP3A genetic polymorphisms on sufentanil consumption in postoperative tumor patients

Liqiang Wu,Ruiyu Zhou,Yichun Wang,Jinfeng Yang,Zhirong Tan,Zhi Li,Jingshi Liu
DOI: https://doi.org/10.3760/cma.j.issn.1673-4378.2019.07.003
2019-01-01
Abstract:Objective To investigate the association between postoperative sufentanil consumption and genetic polymorphisms of mu-opioid receptor (OPRM1), ATP-banding cassette, subfamily B, member 1 gene (ABCB1) and CYP3A in postoperative tumor patients. Methods A total of one hundred and twenty patients [American Society of Anesthesiologists (ASA)ⅠorⅡ, aging 19 to 65] who were scheduled to undergo tumor surgery under general anesthesia were enrolled in this study. Intravenous patient-controlled analgesia with sufentanil was provided postoperatively. Cumulative sufentanil consumption was measured 2, 6, 12, 24 h and 48 h after surgery. The severity of pain was assessed with the Visual Analogue Scale (VAS), while OPRM1 118A﹥G, ABCB1 2677G﹥A/T, ABCB1 3435C﹥T, and CYP3A4*1G and CYP3A5*3 variant alleles were detected. The effects of genetic and non-genetic factors on sufentanil requirements were evaluated with multiple linear regression analysis. Results Patient VAS scores 2, 6, 12, 24 h and 48 h after surgery were obviously associated with cumulative sufentanil doses (P﹤0.05). The 48 h cumulative sufentanil dose after surgery was associated with age (P﹤0.05). Conclusions There was no association between OPRM1, ABCB1, CYP3A genetic polymorphisms and postoperative sufentanil consumption in tumor patients.
What problem does this paper attempt to address?